Melissa Epperly Sells 4,938 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 4,938 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total value of $196,236.12. Following the completion of the sale, the director directly owned 9,900 shares in the company, valued at approximately $393,426. The trade was a 33.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Trading Down 0.5%

Shares of NASDAQ ROIV opened at $39.77 on Friday. Roivant Sciences Ltd. has a 12 month low of $14.50 and a 12 month high of $42.50. The firm has a market capitalization of $28.73 billion, a price-to-earnings ratio of -75.04 and a beta of 1.12. The business has a 50-day moving average of $36.18 and a 200-day moving average of $32.03.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. On average, analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Analyst Ratings Changes

ROIV has been the topic of several research reports. TD Cowen raised their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Guggenheim upped their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. UBS Group set a $55.00 target price on Roivant Sciences in a research note on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.64.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently bought and sold shares of ROIV. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares during the last quarter. Allworth Financial LP increased its stake in shares of Roivant Sciences by 42.1% in the fourth quarter. Allworth Financial LP now owns 2,551 shares of the company’s stock worth $55,000 after buying an additional 756 shares during the period. Clearstead Advisors LLC raised its holdings in Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after buying an additional 1,704 shares during the last quarter. Finally, Root Financial Partners LLC boosted its position in Roivant Sciences by 187.9% during the 1st quarter. Root Financial Partners LLC now owns 2,914 shares of the company’s stock valued at $81,000 after buying an additional 1,902 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.